There is a pattern I have watched play out more times than I can count in Pharma and Biotech. A woman has met or exceeded expectations on her review. Her manager tells her she is valued. Her projects meet (impossible) deadlines. Her peers rely on her. The feedback is strong and consistent. And yet the next level does not materialize. No new scope. No title change. No meaningful shift in how she is positioned inside the organization.
In Pharma and Biotech, especially past a certain level, that relationship changes. Not because performance stops mattering. Because performance stops being enough.
What your leadership room is actually deciding
I spent over a decade inside Pharma HR and talent development, sitting in the conversations that determine who moves and how reviews are calibrated.
In most promotion discussions, the question is not whether she is a reliable performer. That gets settled quickly. The debate is more specific: is she perceived as ready for expanded scope, given the constraints the organization is operating under right now?
And how many of the leaders around the table even know who she is or what she does?
Even in high-functioning cultures, advancement decisions are made inside limiting factors. Budget lines. Headcount. Business priorities. Competing timelines. And they are often shaped by leaders who do not work with you every day. In matrix organizations, that is the part most high performers do not account for. If your work is excellent but visible to a narrow set of stakeholders, your advancement can stall without anyone ever saying no to you directly.
This is why “I’ve earned it” is emotionally accurate and strategically incomplete. When the title becomes the reward for effort, the work starts to feel like a negotiation with the system. I did my part. The organization should do theirs.
But organizations do not promote based on fairness. They promote based on business logic, perceived readiness, and internal consensus among people who may only know you through what others say about you in a room you are not in.
When strong performance becomes the baseline
Pharma and Biotech are full of technically excellent, deeply caring people. That is the nature of the industry. Which means that in this environment, strong performance does not differentiate you the way it once did. It becomes the floor. Being reliable is assumed. Delivering is expected. The question decision-makers are asking is not whether you can do the job you have. It is whether they can see you in the job that does not exist for you yet.
This is why so many high-performing women describe feeling like they are running on a treadmill. They take on another cross-functional project. They present in another leadership forum. They raise their hand for the stretch assignment. And the needle does not move. The work is not the problem. The work is being absorbed into the system without changing how they are positioned in the story leaders are telling themselves about who is ready for what is next.
When performance becomes baseline, advancement shifts to other variables:
- whether the right people can describe your value when you are not in the room
- whether your scope reads as senior-level to people outside your immediate team
- whether the relationships you have built create sponsorship rather than just hidden fans.
The move is from performing well to being understood as promotable. Those are different things, and most Pharma organizations will never tell you that directly.
What happens cognitively when effort stops producing results
As an expert in organizational psychology, I have spent years studying what happens inside high achievers when the system stops responding the way it should. The first response is rarely discouragement. It is analysis.
The brain, which is wired to find patterns and restore predictability, doubles down. It looks for the missing variable. It replays calibration conversations. It creates more detailed IDPs. It builds a more thorough business case. It prepares more carefully for the next review cycle.
This is not weakness. It is the high achiever’s most reliable tool being applied to the wrong problem. If the barrier is not effort, more effort will not move it. If the barrier is visibility, more invisible work deepens the gap. If the barrier is how you are positioned with the people influencing the decision, staying heads-down in execution mode can actually signal the opposite of what you intend.
Pharma organizations are not designed to tell you clearly what is holding you back. The feedback you receive in a performance review often reflects what your manager can say, not the full picture of what was discussed in calibration. Working harder in response to incomplete information is a completely rational response to a system that is not being transparent with you. It is also a response that keeps you exactly where you are.
Why this lands differently for women in this industry
Women in Pharma and Biotech navigate something specific that most career advice does not name. In science-driven corporate environments, there is often an implicit premium on being low-maintenance, agreeable, and consistently excellent. These are the behaviors that earn respect early in your career. They are also the behaviors that can work against your advancement once you reach a certain level.
I watched this pattern repeatedly. Women who had built their reputations on reliability and technical excellence would find that the next level required something different: visibility with leaders outside their immediate team, influence in rooms where decisions were being made before the formal process began, and a positioning narrative that made their value known to people who did not know their work directly. None of those things are rewarded by working harder at what already got them this far.
There is also something specific about how resentment functions here.
Wanting recognition for your contribution is not a character flaw. It is a reasonable response to a system that implied a set of rules and then did not follow them. But when that resentment becomes the lens through which you are making career decisions, it narrows your options.
It focuses energy on what the organization owes you rather than on shaping the conditions that produce what you want. Those are fundamentally different perspectives, and only one of them is within your control.
Building the conditions for promotion
The reframe that changes everything is this: stop treating the title as the thing you want, and start identifying what the title represents. In last week’s article I talked about knowing your “why”. When you are clear on the underlying driver, you can build a more coherent strategy and a more persuasive case.
This is where I work with women inside the Right Move Protocol™: moving from chasing outcomes to shaping the conditions that produce them. That means getting precise about direction, building positioning that makes your strengths legible to the people influencing the decision, creating visibility with stakeholders beyond your immediate team, and investing in relationships that create real sponsorship rather than general appreciation.
It also means releasing the idea that you have to deserve your way to the next level. Deserving is not a business case. The career you want becomes more available when you start operating with the clarity and strategy that the industry actually responds to.
Creating Meaningful Growth
Pharma and Biotech will remain complex. The timelines are long. The stakes are high. Reorgs happen. Headcount freezes happen. The people who advance consistently in this environment are not always the ones who work the hardest. They are the ones who understand how decisions get made, how narratives form around a person’s readiness, and how to make their value transferable when the organizational context changes around them.
A title is a meaningful milestone when it reflects genuine scope and earned influence. But when it becomes the primary object of your focus, it narrows your thinking and your strategy. When you shift attention from the label to the conditions underneath it, something different becomes possible. You stop waiting for the organization to recognize what you already know about yourself. And you start building the kind of career that does not depend on any single leader, team, or cycle to hold its shape.
Next Steps
Learn more about the Your Worthy Career® method inside my book: Your Worthy Career: A Science=Backed Method to Build a Meaningful Career in Pharma and Biotech. Available now on Amazon.I work with a limited number of women in industry. If you’re interested in exploring working together to help you identify your next best role, be seen as an industry leader and build a meaningful career, apply for a consultation here.
